-
-
-
-
-
-
-
BeOne Medicines wins FDA approval for mantle cell lymphoma drug
-
-
-
-
-
-
-
BeOne Medicines (ONC) PT Raised to $412 at Truist Securities
-
-
-
-
-
-
-
4Q25/2026 Biotech Earnings Preview: RBC
-
-
-
-
-
-
-
Truist Securities Starts BeOne Medicines (ONC) at Buy
-
-
-
-
-
-
-
Biotech stocks: Q3 earnings preview
-
-
-
-
-
-
-
BeOne Medicines gets EU approval for BRUKINSA tablet formulation
-
-
-
-
-
-
-
BeOne Medicines (ONC) PT Raised at RBC Capital; 'We See Continued HemeOnc Leadership'
-
433,250 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

